Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ

British Journal of Cancer

Volumn 92, Issue 9, 2005, Pages 1720-1728

  Wulfing P ^a   Kersting, C ^b   Buerger, H ^b   Mattsson, B ^a   Mesters, R ^a   Gustmann, C ^c   Hinrichs, B ^d   Tio, J ^a   Bocker W ^b   Kiesel, L ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c St Vincenz Krankenhaus Limburg   (Germany)

^d Institut für Pathologie   (Germany)

Author keywords

Angiogenesis; Breast cancer; Ductal carcinoma in situ; Growth factors; Immunohistochemistry; Lymphangiogenesis; Receptors

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ESTROGEN RECEPTOR; GROWTH FACTOR; PROGESTERONE RECEPTOR; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER INVASION; CARCINOMA IN SITU; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; ENDOTHELIN-1; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MIDDLE AGED; PROTEIN ARRAY ANALYSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 19944368742     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602567     Document Type: Article

References (48)

1. Bek EL, McMillen MA (2000) Endothelins are angiogenic. J Cardiovasc Pharmacol 36: S135-S139
2. Buerger H, Mommers EC, Littmann R, Simon R, Diallo R, Poremba C, Dockhorn-Dworniczak B, van Diest PJ, Boecker W (2001) Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 194: 165-170
3. Buerger H, Otterbach F, Simon R, Schafer KL, Poremba C, Diallo R, Brinkschmidt C, Dockhorn-Dworniczak B, Boecker W (1999) Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol 189: 521-526
4. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K (1998) Vascular endothelial growth factor induces angiogenesis in vivo. Proc Natl Acad Sci USA 95: 14389-14394
5. Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L, Cortes-Funes H (1997) Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 76: 1215-1220
6. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Taranger-Charpin C (2004) Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n = 905). Br J Cancer 90: 1216-1221
7. De Jong JS, van Diest PJ, van der Valk P, Baak JPA (1998a) Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 184: 44-52
8. De Jong JS, van Diest PJ, van der Valk P, Baak JPA (1998b) Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. J Pathol 184: 53-57
9. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT (1992) The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991
10. Engels K, Fox SB, Whitehouse RM, Gatter KC, Harris AL (1997) Distinct angiogenic patterns are associated with high-grade in situ ductal carcinomas of the breast. J Pathol 181: 207-212
11. Eskens FA (2004) Angiogenesis inhibitors in clinical development; where are we now and where are we going. Br J Cancer 90: 1-7
12. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669-676
13. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31
14. Folkman J, Watson K, Ingber D, Hanahan D (1989) Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61
15. Gasparini G (2001) Clinical significance of determination of surrogate markers of angiogenesis in breast cancer. Crit Rev Oncol Hematol 37: 97-114
16. Gasparini G, Weidner N., Bevilacqua P, Maluta S, Palma PD, Caffo O, Barbareschi M, Boracchi P, Marubini E, Pozza F (1994) Tumour microvessel density, p53 expression, tumour size, and peritumoural lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 12: 454-466
17. Guidi AJ, Fischer L, Harris JR, Schnitt SJ (1994) Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 86: 614-619
18. Guidi AJ, Schnitt SJ, Fischer L, Tognazzi K, Harris JR, Dvorak HF, Brown LF (1997) Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer 80: 1945-1953
19. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellmann S (1996) Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 88: 1764-1769
20. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B (1994) Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 11: 167-180
21. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K (1997) Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276: 1423-1425
22. Kern FG, Lippman ME (1996) The role of angiogenic growth factors in breast cancer progression. Cancer Met Rev 15: 213-219
23. Kinoshita J, Kitamura K, Kabashima A, Saeki H, Tanaka S, Sugimachi K (2001) Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res Treat 66: 159-164
24. Kranz A, Mattfeldt T, Waltenberger J (1999) Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 84: 293-298
25. Luqmani YA, Graham M, Coombes RC (1992) Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br J Cancer 66: 273-280
26. Mason IJ (1994) The ins and outs of fibroblast growth factors. Cell 78: 547-552
27. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A (1993) High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846
28. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard SR, Schlessinger J (1997) Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955-960
29. Mommers EC, Leonhart AM, Falix F, Michalides R, Meijer CJ, Baak JP, Diest PJ (2001) Similarity in expression of cell cycle proteins between in situ and invasive ductal breast lesions of same differentiation grade. J Pathol 194: 327-333
30. Mustonen T, Alitalo K (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129: 895-898
31. Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K (2003) Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 16: 309-314
32. Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3: 110-116
33. Obermaier A, Kucera E, Mayerhofer K, Speiser P, Seifert M, Czerwnka K, Kaider A, Leodolter S, Kainz C, Zeillinger R (1997) Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int J Cancer 74: 455-458
34. Pajusola K, Aprelikova O, Pelicci G, Weich H, Claesson-Welsh L, Alitalo K (1994) Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors. Oncogene 9: 3545-3555
35. Salani D, Di Castro V, Nicotra MR, Rosano L, Tecce R, Venuti A, Natali PG, Bagnato A (2000) Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 157: 1537-1547
36. Smith K, Fox SB, Whitehouse R, Taylor M, Greenall M, Clarke J, Harris AL (1999) Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. Ann Oncol 10: 707-713
37. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor 1α in ovarian cancer cells. J Biol Chem 277: 27850-27855
38. Teo NB, Shoker BS, Jarvis C, Martin L, Sloanel JP, Holcombe C (2002) Vascular density and phenotype around ductal carcinoma in situ (DCIS) of the breast. Br J Cancer 86: 905-911
39. Teo NB, Shoker BS, Jarvis C, Martin L, Sloane JP, Holcombe C (2003) Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 39: 38-44
40. Valtola R, Salven P, Heikkila P, Taipale J, Joensuu H, Rehn M, Pihlajaniemi T, Weich H, deWaal R, Alitalo K (1999) VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154: 1381-1390
41. Van Trappen PO, Steele D, Lowe DG, Baithun S, Beasley N, Thiele W, Weich H, Krishnan J, Shepherd JH, Pepper MS, Jackson DG, Sleeman JP, Jacobs IJ (2003) Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201: 544-554
42. Vleugel MM, Bos R, van der Groep P, Greijer AE, Shvarts A, Stel HV, van der Wall E, van Diest PJ (2004) Lack of lymphangiogenesis during breast carcinogenesis. Clin Pathol 57: 746-751
43. Wülfing P, Diallo R, Kersting C, Wülfing C, Poremba C, Greb RR, Bocker W, Kiesel L (2004a) Endothelin-1, Endothelin-A- and Endothelin-B- receptor expression in preinvasive and invasive breast disease. Oncol Rep 11: 791-796
44. Wulfing P, Diallo R, Kersting C, Wulfing C, Poremba C, Rody A, Greb RR, Böcker W, Kiesel L (2003a) Expression of Endothelin-1, Endothelin-A and Endothelin-B receptor in human breast cancer and correlation with long-term follow-up. Clin Cancer Res 9: 4125-4131
45. Wülfing P, Diallo R, Müller C, Wülfing C, Poremba C, Heinecke A, Rody A, Greb RR, Böcker W, Kiesel L (2003b) Analysis of cyclooxygenase-2 expression in human breast cancer: high throughput tissue microarray analysis. J Cancer Res Clin Oncol 129: 375-382
46. Wülfing P, Kersting C, Tio J, Fischer RJ, Wülfing C, Poremba C, Diallo R, Böcker W, Kiesel L (2004b) Endothelin-1, Endothelin-A- and Endothelin-B-receptor expression is correlated with VEGF expression and angiogenesis in breast cancer. Clin Cancer Res 10: 2393-2400
47. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP (1996) Expresion of vascular endothelial growth factor, its receptor and other angiogenic factors in human breast cancer. Cancer Res 56: 2013-2016
48. Zhukova LG, Zhukov NV, Lichinitser MR (2003) Expression of Flt-1 and Flk-1 receptors for vascular endothelial growth factor on tumor cells as a new prognostic criterion for locally advanced breast cancer. Bull Exp Biol Med 135: 478-481